A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma.
CSPG4
DNA vaccination
comparative oncology
metastasis
osteosarcoma
Journal
Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581
Informations de publication
Date de publication:
02 08 2023
02 08 2023
Historique:
received:
26
04
2023
revised:
24
05
2023
accepted:
08
06
2023
pmc-release:
02
08
2024
medline:
7
8
2023
pubmed:
14
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
The high mortality rate of osteosarcoma (OSA) patients highlights the requirement of alternative strategies. The young age of patients, as well as the rarity and aggressiveness of the disease, limits opportunities for the robust testing of novel therapies, suggesting the need for valuable preclinical systems. Having previously shown the overexpression of the chondroitin sulfate proteoglycan (CSPG)4 in OSA, herein the functional consequences of its downmodulation in human OSA cells were evaluated in vitro, with a significant impairment of cell proliferation, migration, and osteosphere generation. The potential of a chimeric human/dog (HuDo)-CSPG4 DNA vaccine was explored in translational comparative OSA models, including human xenograft mouse models and canine patients affected by spontaneous OSA. The adoptive transfer of HuDo-CSPG4 vaccine-induced CD8
Identifiants
pubmed: 37312451
pii: S1525-0016(23)00315-5
doi: 10.1016/j.ymthe.2023.06.004
pmc: PMC10421998
pii:
doi:
Substances chimiques
Vaccines, DNA
0
Chondroitin Sulfate Proteoglycans
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2342-2359Informations de copyright
Copyright © 2023 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests None of the authors have a conflict of interest to declare.
Références
Am J Vet Res. 2011 Dec;72(12):1631-8
pubmed: 22126691
Exp Hematol Oncol. 2022 Jul 30;11(1):44
pubmed: 35907881
Vet Clin North Am Small Anim Pract. 2007 Nov;37(6):1023-32; v
pubmed: 17950880
Theranostics. 2015 Feb 15;5(5):530-44
pubmed: 25767619
Front Immunol. 2018 Jan 10;8:1911
pubmed: 29375561
J Vet Intern Med. 2017 Jul;31(4):970-978
pubmed: 28557000
Nucl Recept Signal. 2003;1:e012
pubmed: 16604184
FASEB J. 2013 Dec;27(12):4731-44
pubmed: 23970797
Front Oncol. 2022 Apr 01;12:830546
pubmed: 35433427
PLoS One. 2016 Mar 15;11(3):e0150205
pubmed: 26978655
J Immunother Cancer. 2014 Aug 19;2:25
pubmed: 25197555
Vet Comp Oncol. 2021 Jun;19(2):311-352
pubmed: 33427378
J Bone Miner Res. 2013 Apr;28(4):838-47
pubmed: 23169460
J Comp Pathol. 2007 Jan;136(1):65-73
pubmed: 17270206
Acta Vet Scand. 2017 Oct 24;59(1):71
pubmed: 29065898
Nat Rev Cancer. 2020 Dec;20(12):727-742
pubmed: 32934365
Life (Basel). 2022 Dec 14;12(12):
pubmed: 36556464
PLoS Comput Biol. 2021 Sep 27;17(9):e1009450
pubmed: 34570764
Clin Cancer Res. 2016 Sep 1;22(17):4380-90
pubmed: 26994144
J Transl Med. 2022 Oct 11;20(1):464
pubmed: 36221119
Onco Targets Ther. 2019 Apr 03;12:2513-2518
pubmed: 31040694
Cell Mol Immunol. 2020 Mar;17(3):227-236
pubmed: 31611650
J Vet Intern Med. 2011 Jan-Feb;25(1):94-9
pubmed: 21143299
Front Pharmacol. 2022 Oct 17;13:1031527
pubmed: 36324681
Pigment Cell Melanoma Res. 2011 Dec;24(6):1148-57
pubmed: 22004131
Cancers (Basel). 2022 Mar 06;14(5):
pubmed: 35267655
Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16072-16082
pubmed: 32571915
Vet J. 2013 Jan;195(1):41-7
pubmed: 22704137
Biomed Eng Online. 2021 Mar 2;20(1):24
pubmed: 33653371
Nat Commun. 2020 Feb 21;11(1):1008
pubmed: 32081846
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
Curr Top Microbiol Immunol. 2017;405:99-122
pubmed: 25294003
J Transl Med. 2017 Jul 1;15(1):151
pubmed: 28668095
J Immunother Cancer. 2022 May;10(5):
pubmed: 35580930
Cancer Immunol Immunother. 2022 Apr;71(4):851-863
pubmed: 34463793
PLoS One. 2013 Aug 05;8(8):e70689
pubmed: 23940627
Clin Cancer Res. 2014 Jul 15;20(14):3753-62
pubmed: 24874834
Cancer Res. 2005 Aug 1;65(15):6976-83
pubmed: 16061683
Sci Rep. 2016 Jul 26;6:30093
pubmed: 27456063
Int J Mol Sci. 2018 Nov 15;19(11):
pubmed: 30445702
Front Immunol. 2022 Jun 01;13:907550
pubmed: 35720360
J Clin Med. 2021 Jun 14;10(12):
pubmed: 34198693
Transl Oncol. 2022 Feb;16:101318
pubmed: 34942534
Clin Exp Metastasis. 2018 Oct;35(7):641-648
pubmed: 30121939
Vet Comp Oncol. 2021 Mar;19(1):92-98
pubmed: 32729979
Cancers (Basel). 2021 Feb 15;13(4):
pubmed: 33672007
Clin Cancer Res. 2014 Jun 1;20(11):2910-21
pubmed: 24668647
PLoS One. 2012;7(3):e33274
pubmed: 22428007
Pharmacol Res. 2021 Jul;169:105684
pubmed: 34022396
Vaccine. 2006 May 22;24(21):4572-5
pubmed: 16159686
Pediatr Blood Cancer. 2016 Jun;63(6):1006-11
pubmed: 26929018
Ther Adv Med Oncol. 2019 Jun 06;11:1758835919855491
pubmed: 31217827
Can Vet J. 2020 Mar;61(3):301-308
pubmed: 32165755
Pilot Feasibility Stud. 2019 Oct 6;5:114
pubmed: 31608150
Vaccines (Basel). 2020 Apr 06;8(2):
pubmed: 32268572
Br J Cancer. 2013 Oct 15;109(8):2228-36
pubmed: 24064976
Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):466-70
pubmed: 1731316
Cells. 2021 Jan 31;10(2):
pubmed: 33572496
Vet Comp Oncol. 2017 Sep;15(3):996-1013
pubmed: 27146852
Vaccine. 2006 May 22;24(21):4582-5
pubmed: 16188351
Front Immunol. 2021 Apr 14;12:642316
pubmed: 33936058
Vaccines (Basel). 2018 Jul 25;6(3):
pubmed: 30044426
Clin Cancer Res. 2013 Sep 15;19(18):4941-50
pubmed: 24021875
BMC Vet Res. 2019 Dec 21;15(1):467
pubmed: 31864375